Last reviewed · How we verify
Zoloft generic
About Zoloft
Zoloft (sertraline) — originally marketed by Pfizer Inc.. Class: SSRI (Selective serotonin reuptake inhibitor). First approved 1991-12-30.
Approved generic versions (6)
| Generic | Manufacturer | Phase | First approval | Country |
|---|---|---|---|---|
| SERTRALINE | marketed | 1991-01-01 | ||
| Sertraline and Alprazolam XR | Indiana University School of Medicine | marketed | ||
| sertraline fluvoxamine | Second Affiliated Hospital, School of Medicine, Zhejiang University | marketed | ||
| Sertraline HCl | Tri-Service General Hospital | marketed | ||
| Sertraline [Zoloft] | Johns Hopkins University | marketed | ||
| Sertraline + Olanzapine | Weill Medical College of Cornell University | marketed |
Originator patent timeline
Active patents (0)
Expired patents (0)
How small-molecule generic approval works
Generic versions of small-molecule drugs are approved by the FDA via the Abbreviated New Drug Application (ANDA) pathway under the Hatch-Waxman Act of 1984. Sponsors must demonstrate bioequivalence (pharmacokinetic equivalence within tight bounds) and identical chemical composition — no clinical trials in patients are required. Approval typically takes 18-24 months.
This is different from biosimilars for biologic drugs, which use the more complex 351(k) BLA pathway and typically achieve smaller (15-35%) discounts vs the originator. Small-molecule generics typically launch at 60-80% discount, dropping to 85-95% within 2 years.
Subscribe to generic updates
Related
- Zoloft full drug profile
- Biosimilar tracker (for biologic drugs)
- Patent cliff tracker
- Biosimilar vs generic — what's the difference?
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing